Table 1

Baseline characteristics of the study population

SB2 (N=291)INF (N=293)Total (N=584)
Age (years)51.6±11.952.6±11.752.1±11.8
Gender (female)79.7%80.5%80.1%
Race (white)86.6%86.7%86.6%
Height (cm)164.6±9.3164.8±8.6164.7±8.9
Weight (kg)72.3±15.871.9±16.572.1±16.2
BMI (kg/m2)26.6±5.326.5±6.026.6±5.6
Disease duration (years)6.3± 5.96.6±6.06.4±5.9
Rheumatoid factor73.9%71.0%72.4%
Tender joint count (68 joint)23.6±12.324.0±12.223.8±12.3
Swollen joint count (66 joint)14.6±7.814.9±7.714.7±7.8
Duration of methotrexate therapy (months)53.5±49.948.2±45.550.8±47.8
Methotrexate dose (mg/week)14.7±4.214.7±4.114.7±4.2
CRP (mg/L)12.5±18.813.7±19.213.1±19.0
ESR (mm/h)44.5±19.246.7±22.345.6±20.9
Pain VAS (mm)61.2±18.663.3±20.062.3±19.3
Subject GA, VAS (mm)62.9±17.562.7±18.762.8±18.1
Physician GA, VAS (mm)61.7±15.561.8±15.861.7±15.7
  • Data are presented in either mean±SD or percentage (%).

  • BMI, body mass index; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28, disease activity score measured by 28 joints; ESR, erythrocyte sedimentation rate; GA, global assessment of disease activity; HAQ-DI, health assessment questionnaire of disability index; INF, infliximab reference product; SDAI, simplified disease activity index; VAS, visual analogue scale.